Robert J. Paradiso Partner

New Jersey
T 973.597.2404 | F 973.597.2405

Robert’s practice is focused on the life sciences and chemical industries. Over the course of his career, he has counseled clients on the discovery, design, and protection of many successful therapeutic and diagnostic products with important commercial and humanitarian benefits. He is recognized by Chambers USA (2012-2017) as a “phenomenal” lawyer and “practical, strategic thinker” who “is very good at thinking outside the box and looking at every angle and advising on how to best move forward.”

As a registered pharmacist, Robert is able to speak the same language as the researchers, managers, and investors with whom he interacts daily. He is particularly adept at analyzing complex issues and effectively crafting, communicating, and implementing solutions that achieve his clients’ goals–whether for raising capital, closing the deal, or obtaining a bet-the-company patent.

Clients benefit from Robert’s significant experience in virtually all aspects of intellectual property law, including:

  • Patent prosecution
  • Noninfringement
  • Patentability
  • Litigation
  • Freedom to operate
  • Technology transfer

He also regularly advises clients on product acquisition and divestiture, joint ventures and alliances, technology licensing, outsourcing, and other technology-related transactions.

Robert serves as an adjunct professor at Seton Hall University School of Law School, where he teaches patent drafting and prosecution.

Representative Engagements

Obtained a groundbreaking patent that is listed in the FDA Orange Book for a tamper resistant formulation of an FDA-approved narcotic analgesic.
Obtained Orange Book listed patents for a specialty pharmaceutical company specializing in acute hospital care. The patents encompass four currently marketed formulations of an injectable antihypertensive product and were the driving force for the eventual acquisition of the company.
Obtained multiple patents covering a Phase III injectable product for the treatment of adverse effects of chemotherapy.
View More...

Other Distinctions

  • Chambers USA: America’s Leading Lawyers for Business (2012-2016) – Clients note Robert Paradiso "is very good at thinking outside the box, and looking at every angle and advising on how best to move forward." Sources praise Robert for having the ability to “spin gold out of hay” and being “very smart, easy to deal with and a practical strategic thinker.”


Laws of Nature: Myriad and the Prometheus Impact
Bloomberg Life Sciences Law & Industry Report, June 1, 2012
Robert Paradiso
Drafting Method-of-Treatment Claims
New Jersey Law Journal, April 11, 2011
Robert Paradiso
District Court Holds Myriad’s Gene Patents Invalid
Metropolitan Corporate Counsel, June 2010
Robert Paradiso
View More...

Press Mentions

Lowenstein Sandler represented underwriters Roth Capital Partners LLC, Oppenheimer & Company Inc., and Janney Montgomery Scott LLC in connection with Tonix Pharmaceuticals Holding Corp (TNXP) $20.1 million public offering of common stock. The Lowenstein deal team included John (Jack) D. Hogoboom, Ellen Santos, Albert Alsaygh, Rob Paradiso and Irina Ishak. , July 17, 2015
Lowenstein Sandler represented Maxim Group LLC, as placement agent, in connection with a registered direct offering of $4 million for Rock Creek Pharmaceuticals. The Lowenstein deal team included Steven M. Skolnick, Robert J. ParadisoIrina Ishak and Brandon Greenblatt. , June 18, 2015
Lowenstein Sandler represented Maxim Group LLC as sole book-running manager for the $13.1 million underwritten public offering for Provectus Biopharmaceuticals Inc. The Lowenstein deal team included Steven M. Skolnick, Robert J. Paradiso, James B. O’GradyIrina Ishak and Brandon Greenblatt. , June 17, 2015
View More...

Related Areas

Life Sciences
Patent Counseling & Prosecution
The Tech Group


St. John's University School of Law ( J.D. , 1994 )
Long Island University ( B.S. , 1990 ) , Pharmacy

Bar Admissions

New York
New Jersey
United States Patent and Trademark Office